ArticleScientific reports2019
Synthesis and characterization of CaSr-Metal Organic Frameworks for biodegradable orthopedic applications.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Effect of Dimethyloxalylglycine on Stem Cells Osteogenic Differentiation and Bone Tissue Regeneration-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Recent advances in metal-organic frameworks for the diagnosis and treatment of breast cancer.Discover nano · 2026Review
- Bimetallic Fe/K γ-cyclodextrin metal-organic frameworks with enhanced loading capacity and tunable release behavior.Scientific reports · 2026Article
- Co-Delivery of Ca-MOF and Mg-MOF Using Nanoengineered Hydrogels to Promote In Situ Mineralization and Bone Defect Repair: In Vitro and In Vivo Analysis.Advanced healthcare materials · 2025Article
- Synthetic Strategy for mRNA Encapsulation and Gene Delivery with Nanoscale Metal-Organic Frameworks.Advanced functional materials · 2025Article
- The synergy of metal-organic frameworks and biomaterials for bone tissue engineering: recent advances, challenges, and future recommendations.Nanoscale advances · 2025Review
- Synthesis and Osteoinductive Properties of Nanosized Lithium-Modified Calcium-Organic Frameworks.Materials (Basel, Switzerland) · 2025Article
- Application of metal-organic frameworks-based functional composite scaffolds in tissue engineering.Regenerative biomaterials · 2024Review
- Preparation and Evaluation of Aminomalononitrile-Coated Ca-Sr Metal-Organic Frameworks as Drug Delivery Carriers for Antibacterial Applications.ACS omega · 2023Article
- Inorganic/organic combination: Inorganic particles/polymer composites for tissue engineering applications.Bioactive materials · 2023Article
- Metal-Organic Frameworks for Drug Delivery: A Design Perspective.ACS applied materials & interfaces · 2021Review
- Metal-Organic Framework (MOF)-Based Biomaterials for Tissue Engineering and Regenerative Medicine.Frontiers in bioengineering and biotechnology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal-organic frameworks (MOFs) formed from metals and organic ligands, are crystalline materials that are degradable in aqueous medium, and capable of releasing Ca and Sr ions. In this manuscript, the ability of MOFs to degrade and release osteogenic Ca and Sr ions was investigated. MOFs were generated by choosing osteoinductive Ca and Sr metals, and an organic ligand 1,3,5 tricarboxylicbenzene (H3BTC) as a linker. These MOFs were able to induce in vitro biomineralization from pre-osteoblastic MC3T3 cells and human mesenchymal stem cells (hMSCs). Moreover, these MOFs (when loaded with dimethyloxalylglycine (DMOG)) induced vascular endothelial production from hMSCs. qRT-PCR analysis performed on hMSCs (isolated from femoral heads of patients undergoing joint arthroplasty) treated with MOFs crystals suggested that the CaSr-MOFs by themselves can upregulate osteogenic genes in hMSCs, which is the first time to our knowledge that this has been observed from MOFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.